Amidophosphine−phosphinite ligands (AMPP) derived from
(S)-N-benzylmandelamide
((S)-R,R‘-benzylmandelNOP (S)-1 (R = R‘ = phenyl)
and (S)-7 (R = phenyl, R‘ =
cyclopentyl)),
(S)-N-methylmandelamide
((S)-R,R‘-methylmandelNOP (S)-2 (R =
R‘ = phenyl) and (S)-8
(R = phenyl, R‘ = cyclopentyl)),
(S)-N-methyllactamide
((S)-R,R‘-methyllactaNOP (S)-3
(R
= R‘ = phenyl) and (S)-9 (R = phenyl, R‘
= cyclopentyl)), and (S)-2-(hydroxymethyl)-2-pyrrolidinone ((S)-R,R‘-oxoProNOP
(S)-4−6 and
(S)-10 (R, R‘ = phenyl, cyclohexyl,
cyclopentyl)) have been prepared in high yields (60−94%) and reacted with
rhodium precursors
to prepare neutral “Rh{AMPP}” complexes
11−26 of general formula
[Rh{AMPP}X]2, where
X = Cl, I, OCOCH3, OCOCF3, and
OCOC3F7. The crystal structure of
[Rh{(S)-Ph,Ph-methylmandelNOP}Cl]2 (12) has been
determined. The rhodium atom has a cis
square-planar coordination, and the seven-membered chelate ring has a boat
conformation with
the nitrogen atom in the mean plane RhP2. Complexes
11−26 have been used as catalyst
precursors for the asymmetric hydrogenation of
dihydro-4,4-dimethyl-2,3-furandione (27)
and N-benzylbenzoylformamide (29) giving the
corresponding optically active hydroxy
compounds 28 and 30 in high yields and low to
high enantiomeric excesses (28−98.7% ee
and 13−87% ee, respectively). Catalytic activities (turnover
frequency at 50% conversion
at room temperature up to 3300 h-1) as well
as the enantioselectivities depended strongly
on the nature of the substituents on phosphorus as well as on the
nature of the non chiral
ligands. Catalyst precursor
[Rh{(S)-Cp,Cp-oxoProNOP}OCOCF3]2
afforded (R)-pantolactone
in 98.7% ee.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.